INDICATIONS AND USAGE（适应症）

OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH.

DOSAGE（服用剂量）

The recommended dosage of OPSUMIT is 10 mg once daily for oral administration. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.

ADVERSE REACTIONS（不良反应）

Embryo-fetal Toxicity

Hepatotoxicity

Fluid Retention

Decrease in Hemoglobin

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1e484a50-55db-4b85-8c57-6cd1b0353abd/spl-doc?hl=Opsumit

Opsumitinformation